Insmed is a biopharmaceutical company that develops drugs to treat serious and rare diseases. The company's lead product candidate is ARIKAYCE, which is being developed to treat patients with nontuberculous mycobacterial lung disease. Insmed is also developing drugs to treat other respiratory diseases, as well as rare diseases such as lipodystrophy. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.